Vera Therapeutics (VERA) Cash from Operations (2020 - 2026)

Vera Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 106500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 95.75% year-over-year to 106500000.0; the trailing twelve-month figure through Mar 2026 stood at 293198000.0 (down 88.85% YoY), and the FY2025 full-year result was 241104000.0, down 79.02% from the prior year.
• Cash from Operations for Q1 2026 stood at 106500000.0, down from 69994000.0 in the prior quarter.
• The five-year high for Cash from Operations was 8981000.0 in Q1 2022, with the low at 106500000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 37768235.29 across 5 years, with a median of 26292000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations tumbled 235.89% — and 2023, when it advanced 6.63%.
• Vera Therapeutics' Cash from Operations stood at 21162000.0 in 2022, then fell by 18.82% to 25144000.0 in 2023, then tumbled by 55.83% to 39182000.0 in 2024, then plunged by 78.64% to 69994000.0 in 2025, then sank by 52.16% to 106500000.0 in 2026.
• The last three Cash from Operations figures came in at 106500000.0 (Q1 2026), 69994000.0 (Q4 2025), and 61906000.0 (Q3 2025), per Business Quant data.